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Introduction
biological activities of ET-1 are mediated mainly through two receptor subtypes, the ET A and ET B Since the isolation and identification of endothelins as receptors. Both receptor subtypes are expressed in very important vasoconstrictor peptides in 1988, clincardiac myocytes and coronary vessels. Thus the ical and experimental evidence suggests that endothelmolecular basis for an autocrine/paracrine action of ins play an important role in cardiac and vascular endothelin in the myocardial tissue is present. pathology associated with heart failure. Because of the frequency of heart failure in end-stage renal disease, this issue is definitely also of interest to the clinical
Action of endothelin in the heart
nephrologist.
Though secreted predominantly abluminally by Soon after discovery of ET-1, this vasoactive substance endothelial cells, plasma concentrations of endothelin-1 was reported to have several biological actions on ET-1 are increased two to threefold in patients with cardiac tissue. In human myocardium in vitro endoheart failure irrespective of aetiology [1] . As with thelin has been shown to exert a positive inotropic noradrenaline, plasma levels of ET-1 and big effect via sensitization of cardiac myofilaments to calendothelin-1, the inactive precursor of ET-1, are of cium and activation of the sodium proton exchanger prognostic significance, predicting worsening heart fail- [6 ] . The positive inotropic effect is accompanied by ure, need for hospitalization, and death [2] . Plasma prolongation of the duration of the action potential endothelin is correlated closely to the degree of heart [7] . This pharmacological action of ET-1 may contribfailure in patients categorized according to the classiute to the pro-arrythmogenic property of the peptide fication of the New York Heart Association. These when it is endogenously released or exogenously observations strongly suggest a pathophysiological role applied [8, 9] . for endothelin in chronic heart failure. From in vitro
Endothelins also affect heart function indirectly via and in vivo studies studies endothelin is considered to profound coronary vasoconstriction. In contrast to the function more as a local regulator than as a systemic positive inotropic and chronotropic effects seen in hormone [3] . Indeed, local endothelin synthesis has isolated heart studies, a decrease in cardiac output is been observed, confirming the hypothesis of an autocseen when endothelin is infused into the intact animal rine/paracrine endothelin system in the heart. Neonatal
[10]. This may be the consequence of the vasoconstricrat cardiac myocytes express preproET-1 mRNA and tor action of endothelin and the resulting decline in synthesize and secrete mature endothelin-1 [4] . myocardial perfusion as well as increase in afterload. ET-1 is produced from the 38 residue inactive interIn accordance with this suggestion, inhibition of coronmediate big ET-1 via specific cleavage. The protease ary constriction by adenosine unmasked the positive that catalyses the conversion, endothelin-converting inotropic effect of ET-1 [11] . Finally, cell culture enzyme ( ECE ), is expressed in the endocardium and studies demonstrate that endothelin is a potent growth myocardium, and constitutes a potential regulatory factor for cardiomyocytes [12] . Recent in vitro and in vivo studies suggest that ET-1 Correspondence and offprint requests to: Michael Bö hm, Klinik III is involved in the mechanism by which angiotensin fü r Innere Medizin, Joseph-Stelzmann-Str. 9, D-50924 Kö ln, Germany. Email: michael.boehm@medizin.uni-koeln.de induces cardiac hypertrophy. The cardiac endothelin atria and right ventricles of patients with congestive heart failure compared to non-failing control myocardium [16 ] .
The source of elevated tissue ET-1 in congestive heart failure is unclear. Several mechanisms have been discussed. One possibility is an increased production of ET-1 via enhanced synthesis of preproendothelin-1 (ppET-1). Ventricular hypertrophy and congestive heart failure have been associated with increased myocardial expression of ppET-1 mRNA in experimental animal models [13, 15, 16 ] 
Among the ECE identified, the membrane-bound metalloprotease ECE-1 is the major ET-1-forming enzyme in the cardiovascular system. ECE-activity in left ventricular membrane preparations did not significantly differ between failing hearts and non-failing donor hearts. These data correlate with findings on mRNA concentrations, indicating unchanged ECE-1 mRNA-expression.
Apart from altered ET-1 production, decreased clearance of ET-1 within the myocardium may also occur. Several in vivo and in vitro data raise the possibility of a local clearance mechanism mediated by ET B receptors [18] . Since ET B receptors are downregulated in left ventricular myocardium from patients with end-stage heart failure, this mechanism may contribute to the elevated tissue ET-1 levels observed in these patients [15] . In contrast to the decreased ET B receptor Fig. 1 . Proteolytic processing of preproendothelin-1 and big expression, increased ET A receptor density has been endothelin-1 (=proendothelin-1) in biosynthesis of mature reported in end-stage heart failure due to dilated endothelin-1 and major physiological effects of endothelin-1 via cardiomyopathy [6, 15, 19 Thus a relative shift in endothelin receptor expression in favour of the ET A subtype occurs. Although the number of ET A receptor, is increased, ET-1 induced system is activated in association with an activated inositol phosphate formation is unchanged in the failtissue renin-angiotensin system in transgenic ing left ventricular myocardium [19] . These findings TG(mREN2)27 rats [13] . In a neonatal rat cell culture indicate that the ET A receptor signalling pathway is model, Ang II stimulates cardiac myocyte hypertrophy desensitized in end-stage heart failure. A candidate via paracrine release of TGF-b 1 and ET-1 from cardiac mechanism may be the agonist-induced phosphorylfibroblasts [14] .
ation of the ET A -receptor protein by G-proteincoupled receptor kinases.
Regulation of the myocardial endothelin system in the failing heart Conclusions and perspectives
In chronic human heart failure, alterations of the tissue In the left ventricular myocardium of patients with dilated cardiomyopathy, a consistent and significant endothelin system occur. Elevated endogenous ET-1 concentrations due to decreased cardiac clearance and approximately 1.5-2.5-fold increase in immunoreactive ET-1 content has been observed [6, 15] . In contrast, changes in the ET receptor expression pattern in favour of the ET A receptor may have important implications tissue endothelin concentrations seem unchanged in endothelin and regulation of endothelin receptors in isolated for the pathophysiology of heart failure. Antagonists human nonfailing and failing myocardium. 
